BioAtla Investor Presentation Deck

Potential market opportunity in undifferentiated pleomorphic sarcoma (UPS) ~15% ~55% bicatla 2nd most common Soft Tissue Sarcoma (STS) subtype¹,2 patients developing recurrent or metastatic disease ³,4 0 1 year Targeted therapies specifically approved to treat UPS Median time to metastatic/local recurrence 4,5,6 Available Treatment: 1L: Approved treatments for sarcoma ORR ~15%7 ¹Brennan MF, Antonescu CR, Moraco N, Singer S. Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg. 2014;260(3):416-21; ² Penel N, bindre J-M, Giraud A, Terrier P, Ranchere-Vince D, Collin F, et al. Presentation and outcome of frequent and rare sarcoma histologic subtypes: a study of 10,262 patients with localized visceral/soft tissue sarcoma managed in reference centers. Cancer. 2018;124(6):1179-87; ³Vodanovich DA, Spelman T, May D, Slavin J, Choong PFM. Predicting the prognosis of undifferentiated pleomorphic soft tissue sarcoma: a 20-year experience of 266 cases. ANZ J Surg. 2019;89(9):1045-1050; 4Roland CL, May CD, Watson KL, et al. Analysis of Clinical and Molecular Factors Impacting Oncologic Outcomes in Undifferentiated Pleomorphic Sarcoma. Ann Surg Oncol. 2016;23(7):2220-2228; 5Delisca GO, Mesko NW, Alamanda VK, et al. MFH and high-grade undifferentiated pleomorphic sarcoma-what's in a name?. J Surg Oncol. 2015;111(2):173-177; "Winchester D, Lehman J, Tello T, et al. Undifferentiated pleomorphic sarcoma: Factors predictive of adverse outcomes. J Am Acad Dermatol. 2018;79(5):853-859; 7Product USPIS ORR, objective response rate (best objective response as confirmed complete response or partial response) BioAtla| Overview 24

View entire presentation